- Home
- TLSI vs TEI Comparison
TLSI vs TEI Comparison
Compare TLSI & TEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- TEI
- Stock Information
- Founded
- TLSI 2010
- TEI 1993
- Country
- TLSI United States
- TEI United States
- Employees
- TLSI N/A
- TEI N/A
- Industry
- TLSI Medical Specialities
- TEI Finance Companies
- Sector
- TLSI Health Care
- TEI Finance
- Exchange
- TLSI Nasdaq
- TEI Nasdaq
- Market Cap
- TLSI 244.3M
- TEI 282.9M
- IPO Year
- TLSI N/A
- TEI N/A
- Fundamental
- Price
- TLSI $4.73
- TEI $6.24
- Analyst Decision
- TLSI Strong Buy
- TEI
- Analyst Count
- TLSI 4
- TEI 0
- Target Price
- TLSI $11.13
- TEI N/A
- AVG Volume (30 Days)
- TLSI 118.6K
- TEI 142.4K
- Earning Date
- TLSI 11-13-2025
- TEI 01-01-0001
- Dividend Yield
- TLSI N/A
- TEI 10.51%
- EPS Growth
- TLSI N/A
- TEI N/A
- EPS
- TLSI N/A
- TEI N/A
- Revenue
- TLSI $35,990,000.00
- TEI N/A
- Revenue This Year
- TLSI $56.79
- TEI N/A
- Revenue Next Year
- TLSI $54.15
- TEI N/A
- P/E Ratio
- TLSI N/A
- TEI N/A
- Revenue Growth
- TLSI 45.50
- TEI N/A
- 52 Week Low
- TLSI $3.42
- TEI $4.35
- 52 Week High
- TLSI $5.88
- TEI $5.39
- Technical
- Relative Strength Index (RSI)
- TLSI 48.36
- TEI 54.40
- Support Level
- TLSI $4.42
- TEI $6.09
- Resistance Level
- TLSI $4.67
- TEI $6.42
- Average True Range (ATR)
- TLSI 0.23
- TEI 0.10
- MACD
- TLSI -0.03
- TEI -0.02
- Stochastic Oscillator
- TLSI 61.87
- TEI 36.36
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.